India’s Biocon has received approval from the country’s drug regulator to market, Itolizumab injection, to treat cytokine release syndrome (CRS) in moderate to severe acute respiratory distress syndrome (ARDS) in COVID-19 patients, a company statement said.
In 2013, Biocon had launched Itolizumab, an anti-CD6 IgG1 monoclonal antibody biologic therapy for treating chronic plaque psoriasis, which it has now repurposed for treating COVID-19 patients.
The SARS-CoV-2 virus has been observed to induce an overreaction of the immune system, generating a large number of cytokines that can cause severe damage to the lungs and other organs.
The virus can cause, in the worst scenario, multi-organ failure and even death.
The approval of Itolizumab, from the drug regulator is based on the results from the successful conclusion of a randomised, controlled clinical trial at multiple hospitals in Mumbai and New Delhi, the statement said.
India, ranked third after the United States and Brazil for the number of confirmed COVID-19 cases in the world, has 283,407 active cases with 22,123 deaths reported so far.
Edited By: Abdulfatah Babatunde (NAN)
- Barca’s Pique calls for wholesale changes after “shameful” defeat
- INEC seeks stakeholders collaboration in instituting electoral transparency
- Bayern Munich must stay grounded in spite of Barca demolition, coach says
- FC Barcelona’s Umtiti tests positive for COVID-19
- Bauchi Gov. condoles family of murdered lawmaker, Mante
- Football united behind Infantino, FIFA general secretary says
- Council approves health care provision fund guideline
- Labour ministry denies complicity in human trafficking
- UN ‘strongly condemns’ rights abuses in Cameroon
- Tourism operators reveal Top 10 romantic destinations for honeymoon in Nigeria